全文获取类型
收费全文 | 173645篇 |
免费 | 12253篇 |
国内免费 | 4114篇 |
专业分类
耳鼻咽喉 | 2736篇 |
儿科学 | 2503篇 |
妇产科学 | 2401篇 |
基础医学 | 26336篇 |
口腔科学 | 4021篇 |
临床医学 | 17794篇 |
内科学 | 30350篇 |
皮肤病学 | 4595篇 |
神经病学 | 13111篇 |
特种医学 | 9164篇 |
外国民族医学 | 21篇 |
外科学 | 21574篇 |
综合类 | 6775篇 |
现状与发展 | 16篇 |
一般理论 | 32篇 |
预防医学 | 9648篇 |
眼科学 | 4426篇 |
药学 | 16158篇 |
38篇 | |
中国医学 | 3768篇 |
肿瘤学 | 14545篇 |
出版年
2024年 | 245篇 |
2023年 | 1712篇 |
2022年 | 4659篇 |
2021年 | 7100篇 |
2020年 | 4121篇 |
2019年 | 4744篇 |
2018年 | 5477篇 |
2017年 | 4614篇 |
2016年 | 5466篇 |
2015年 | 7670篇 |
2014年 | 9047篇 |
2013年 | 9994篇 |
2012年 | 14750篇 |
2011年 | 14633篇 |
2010年 | 8559篇 |
2009年 | 7209篇 |
2008年 | 9958篇 |
2007年 | 9568篇 |
2006年 | 8750篇 |
2005年 | 8143篇 |
2004年 | 6813篇 |
2003年 | 5991篇 |
2002年 | 5116篇 |
2001年 | 4015篇 |
2000年 | 3729篇 |
1999年 | 3180篇 |
1998年 | 1492篇 |
1997年 | 1245篇 |
1996年 | 958篇 |
1995年 | 855篇 |
1994年 | 753篇 |
1993年 | 537篇 |
1992年 | 1085篇 |
1991年 | 955篇 |
1990年 | 888篇 |
1989年 | 791篇 |
1988年 | 673篇 |
1987年 | 651篇 |
1986年 | 492篇 |
1985年 | 482篇 |
1984年 | 339篇 |
1983年 | 259篇 |
1982年 | 158篇 |
1981年 | 201篇 |
1980年 | 149篇 |
1979年 | 264篇 |
1978年 | 183篇 |
1977年 | 141篇 |
1976年 | 166篇 |
1974年 | 164篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献52.
A typical time series in functional magnetic resonance imaging (fMRI) exhibits autocorrelation, that is, the samples of the time series are dependent. In addition, temporal filtering, one of the crucial steps in preprocessing of functional magnetic resonance images, induces its own autocorrelation. While performing connectivity analysis in fMRI, the impact of the autocorrelation is largely ignored. Recently, autocorrelation has been addressed by variance correction approaches, which are sensitive to the sampling rate. In this article, we aim to investigate the impact of the sampling rate on the variance correction approaches. Toward this end, we first derived a generalized expression for the variance of the sample Pearson correlation coefficient (SPCC) in terms of the sampling rate and the filter cutoff frequency, in addition to the autocorrelation and cross‐covariance functions of the time series. Through simulations, we illustrated the importance of the variance correction for a fixed sampling rate. Using the real resting state fMRI data sets, we demonstrated that the data sets with higher sampling rates were more prone to false positives, in agreement with the existing empirical reports. We further demonstrated with single subject results that for the data sets with higher sampling rates, the variance correction strategy restored the integrity of true connectivity. 相似文献
53.
综述近年中医药治疗慢性前列腺炎的临床研究,认为本病病因病机之核心在于脾肾亏虚为本,湿热、痰浊、瘀毒为标,病久则伤及脾肾,由实转虚。中医内治法主要以辨证论治、辨病论治或单方验方为主,外治法以中药洗浴、中药灌肠、肛门给药、针灸为主。中医药治疗本病优势明显。应继续完善对中医药作用机制的认识,制订统一的辨证论治及疗效评价标准,针对效果显著的名方开展研究。 相似文献
54.
Xia Li Wang Junni Xie Xishao Xiang Shilong Zhang Xiaohui Chen Jianghua Han Fei 《中华肾脏病杂志》2020,36(7):497-502
Objective To observe the clinical characteristics and prognosis of patients with rapidly progressive glomerulonephritis (RPGN) caused by lupus nephritis, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, or primary glomerulonephritis who were treated with peritoneal dialysis (PD) and then withdrew PD because of renal recovery. Methods Data of the above patients were retrospectively analyzed. The patients were diagnosed as RPGN and received PD therapy in Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University from February 2009 to August 2018. The patients were divided into early withdrawal group (PD time≤183 days, n=24) and late withdrawal group (PD time>183 day, n=24). The differences of clinical characteristics between the two groups were compared. The cumulative incidence of adverse events in both groups was analyzed using Kaplan-Meier curves. Cox proportional hazards model was used to analyze the risk factors influencing the prognosis of patients. Results Forty-eight RPGN patients were included. The median time of maintaining PD was 178(76, 378) days. Compared with the late withdrawal group, the patients in early withdrawal group had lower levels of urine volume, serum albumin and parathyroid hormone, and lower rates of gross hematuria and hypertension at the beginning of PD, and received higher rates of methylprednisolone impulse, combined immunosuppressive agents, and hemodialysis or continuous renal replacement therapy (all P<0.05). At the time of PD withdrawal, the levels of serum creatinine, serum calcium, serum albumin and parathyroid hormone in the early withdrawal group were significantly lower than those in the late withdrawal group (all P<0.05). The Kaplan-Meier curves showed that there was no significant difference in the cumulative survival of patients in both groups (log-rank test χ2=3.485, P=0.062). Cox regression analysis revealed serum creatinine≥209 μmol/L at the time of PD withdrawal was an independent risk factor for poor prognosis (HR=5.253,95%CI 1.757-15.702, P=0.003). Conclusions PD can be used for RPGN patients caused by lupus nephritis, ANCA-associated vasculitis and primary nephritis. Serum creatinine≥209 μmol/L at the time of PD withdrawal is an independent risk factor for poor prognosis. 相似文献
55.
56.
57.
58.
59.
60.